ADMA - ADMA Biologics secures new European patent related to S. pneumonia infections

ADMA Biologics (NASDAQ:ADMA) announces that the European Patent Office (EPO) has issued Patent No. 3375789, to the Company. Shares up 2.2% premarket at $1.41. This patent relates to the treatment and prevention of S. pneumonia infections, and in particular, to standardized hyperimmune globulins containing elevated antibody titers for a plurality of S. pneumoniae serotypes. This new patent complements ADMA’s existing U.S. Patent Nos. 10,259,865 and 11,084,870.

For further details see:

ADMA Biologics secures new European patent related to S. pneumonia infections